全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report

Transcription

1 /wepdwukltuyot 全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report 联 系 购 买 电 话 : 公 司 名 称 : 佐 思 信 息 公 司 地 址 : 北 京 市 海 淀 区 苏 州 街 18 号 院 长 远 天 地 大 厦 A2 座 室 (100080) 摘 要 This report analyzes the worldwide markets for Multiple Sclerosis Therapeutics in US$ Billion. The report provides separate comprehensive analytics for the US, Japan, Europe and Rest of World. Annual estimates and forecasts are provided for each region for the period 2006 through The report profiles 45 companies including Bayer Schering Pharma AG, Biogen Idec Inc., Elan Pharmaceuticals, Inc., Genzyme Corp, Merck Serono SA, Novartis AG, Sanofi-Aventis SA, and Teva Pharmaceuticals Industries Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources. Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location. The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report. Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

2 目 录 及 图 表 I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations Disclaimers Data Interpretation & Reporting Level Quantitative Techniques & Analytics Product Definitions and Scope of Study II. EXECUTIVE SUMMARY 1. MARKET HIGHLIGHTS Market Snapshots Market Drivers Market Restraints Major Players 2. MARKET OVERVIEW Increasing Prevalence of Multiple Sclerosis Table 1: World Multiple Sclerosis Prevalence in Thousands by Select Countries for Years 2001 through 2010 (includes corresponding Graph/Chart) Table 2: Prevalence by Types of Multiple Sclerosis (includes corresponding Graph/Chart) MS Therapeutics in the Market Key Multiple Sclerosis Drugs Interferon Drugs Beta Interferon Drugs in Multiple Sclerosis Treatment Non-Interferon Drugs Non-Interferon Drugs in Multiple Sclerosis Treatment High Unmet Need and Rich Pipeline to Expand MS Market Challenges Ahead 3. MARKET TRENDS Interferon-based Drugs Dominate Multiple Sclerosis Market Sales Dip Inevitable for Current Therapies Tough Times Ahead for Betaseron Oral Drugs in Pipeline to Alter Market Dynamics in MS Therapies Competitive Landscape Table 3: Global Multiple Sclerosis Market by Leading Drugs (2008 & 2009): Percentage Share Breakdown for Copaxone, Avonex, Rebif, Betaseron, and Tysabri (includes corresponding Graph/Chart) 4. MULTIPLE SCLEROSIS - DRUG PIPELINE Recent Clinical Trial Activity - An Drugs Under Development for Treating Multiple Sclerosis FTY 720 (Fingolimod) Mylinax

3 Laquinimod Alemtuzumab Teriflunomide BG-12 (Oral Fumarate) Rituxan/MabThera (Rituximab) Vaccines for Multiple Sclerosis 5. PRODUCT OVERVIEW Definition Causes of Multiple Sclerosis Different Forms of Multiple Sclerosis Pathology 6. RECENT INDUSTRY ACTIVITY Acorda Therapeutics Obtains FDA Approval for Fampridine-SR to treat Multiple Sclerosis Novartis Obtains Priority Review Status for Oral Fingolimod from US FDA Copaxone Receives FDA Approval for Patients with First Clinical Episode Suggestive of MS Novartis Obtains FDA Approval for Extavia Merck Serono Collaborates with Brigham and Women's Hospital to Extend Multiple Sclerosis Research Merck Serono Announces Encouraging Phase III Results of Oral Mylinax Merck Serono Acquires Rights to Apitope s Multiple Sclerosis Approach Teva and Active Biotech Obtains Fast Track Status from FDA for Oral Laquinimod Genzyme Signs an Agreement with Bayer Healthcare EMD Serono to Set Up Research Facility in Massachusetts EMD Serono Enters into a Partnership with Fast Forward Biogen Idec Secures US-FDA Approval for Production Process of TYSABRI Biogen Idec Secures Fast Track Designation from US-FDA for PEGylated Interferon Beta-1a Bayer Schering Pharma Receives SFDA of China Approval for Betaferon Merck Serono Signs an Agreement with Bionomics Orasi Medical Establishes New Office in Tokyo Merck Serono and Ambrx to Extend Collaboration for Multiple Sclerosis Kineta Acquires Novel Therapeutic Compounds from Airmid MediciNova Enters into Agreement with Avigen Biogen Idec Takes Over Facet Biotech Teva Pharmaceutical Industries to Take over CoGenesys

4 Merck Serono Introduces RebiSmartTM Electronic Injection Device Bayer to Launch Betaferon Titration Pack MediciNova Announces Phase II Clinical Trial Results of The Myelin Repair Foundation Signs Strategic Deal with Dalton Pharma Services Acorda Therapeutics Takes Over Neurorecovery Bayer to Introduce 30-Gauge Needle for Betaferon Biogen Idec Commences Late-Stage Trial of Oral Compound Bayer Acquires Biologics Manufacturing Plant from Novartis 7. FOCUS ON SELECT PLAYERS Bayer Schering Pharma AG (Germany) Biogen Idec Inc. (US) Elan Pharmaceuticals, Inc. (US) Genzyme Corp. (US) Merck Serono SA (Switzerland) Novartis AG (Switzerland) Sanofi-Aventis SA (France) Teva Pharmaceuticals Industries Limited (Israel) 8. GLOBAL MARKET PERSPECTIVE Table 4: World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Geographic Region - US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 Table 5: World 10-year Perspective for Multiple Sclerosis Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2006, 2009 & 2015 Table 6: World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Leading Drugs - Copaxone, Avonex, Rebif, Betaseron, Tysabri, and Other Drugs Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 Table 7: World 10-year Perspective for Multiple Sclerosis Therapeutics by Leading Drugs - Percentage Breakdown of Dollar Sales for Copaxone, Avonex, Rebif, Betaseron, Tysabri, and Other Drugs for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart) III. MARKET 1. THE UNITED STATES Table 8: US Multiple Sclerosis Prevalence in Thousands for Years 2001 through 2010

5 Strategic Corporate Developments Key Players Biogen Idec, Inc. Elan Pharmaceuticals, Inc. EMD Serono, Inc. Genzyme Corp. Table 9: US Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart) 2. JAPAN Table 10: Japanese Multiple Sclerosis Prevalence in Thousands for Years 2001 through 2010 Strategic Corporate Development Table 11: Japanese Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through EUROPE Table 12: Multiple Sclerosis Prevalence in Select European Countries for Years 2001 through 2010 (includes corresponding Graph/Chart) Low Penetration to Fuel Growth in European MS DMDs Market Oral Medication for MS in Near Future Strategic Corporate Development Key Players Bayer Schering Pharma AG (Germany) Merck Serono SA (Switzerland) Novartis AG (Switzerland) Sanofi-Aventis SA (France) Table 13: European Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through REST OF WORLD

6 Increasing Incidence of Multiple Sclerosis in Canada Strategic Corporate Developments Key Player Teva Pharmaceuticals Industries Limited (Israel) Table 14: Rest of World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through 2015 IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 45 (including Divisions/Subsidiaries - 51) Region/Country Players The United States 26 Canada 3 Japan 1 Europe 18 France 1 Germany 4 The United Kingdom 3 Rest of Europe 10 Asia-Pacific (Excluding Japan) 2 Middle East 1